Capstone Therapeutics Corp. (NASDAQ:CAPS – Get Free Report) was the recipient of a large growth in short interest in September. As of September 15th, there was short interest totaling 92,396 shares, a growth of 73.0% from the August 31st total of 53,416 shares. Based on an average daily trading volume, of 235,825 shares, the short-interest ratio is currently 0.4 days. Currently, 0.7% of the shares of the stock are sold short.
Capstone Therapeutics Trading Down 2.8%
NASDAQ CAPS opened at $0.14 on Thursday. The firm has a market cap of $2.88 million, a price-to-earnings ratio of -0.04 and a beta of -1.50. Capstone Therapeutics has a one year low of $0.14 and a one year high of $1.44. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.39 and a current ratio of 0.99. The firm has a 50 day simple moving average of $0.21 and a 200-day simple moving average of $0.33.
Wall Street Analyst Weigh In
Separately, Weiss Ratings lowered shares of Capstone Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research note on Tuesday, September 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.
Capstone Therapeutics Company Profile
Capstone Therapeutics Corporation was a U.S.-based biotechnology company focused on developing peptide-based therapies for diseases involving fibrosis, scarring and abnormal tissue repair. Publicly available information about the company’s current operations is limited.
Its principal disclosed product candidate was AZX100, a synthetic peptide designed to influence cellular pathways associated with scar formation and fibrotic disease. The candidate was investigated for potential applications involving conditions such as dermal scarring and pulmonary fibrosis, although the available historical information does not establish a currently marketed product.
Capstone Therapeutics was based in the United States and appeared to operate primarily as a development-stage pharmaceutical company rather than as a commercial drug manufacturer.
Further Reading
- Five stocks we like better than Capstone Therapeutics
- Anthropic’s IPO Could Put Amazon’s and Alphabet’s Paper Profits to the Test
- Microsoft’s AI Spending Didn’t Change—Wall Street’s View of It Did
- Cleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket Reach
- L3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock
Receive News & Ratings for Capstone Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capstone Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
